ALX Oncology Holdings Inc. (ALXO) revenue
ALX Oncology Holdings Inc. (ALXO) reported revenue of $1.18M in fiscal 2020 (the year ended December 31, 2020). That is 75.4% lower than the $4.80M of fiscal 2019. Figures as of 18 Nov 2026, 10:14 UTC, from the company's filings with the SEC and Yahoo Finance.
Key facts
- Revenue, fiscal 2020
- $1.18M
- Change on fiscal 2019
- −75.4%
- Highest on record
- $4.80Mfiscal 2019
- Lowest on record
- $1.18Mfiscal 2020
- Fiscal years on record
- 32018–2020
Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Amounts are in USD. Figures, not advice.
ALX Oncology Holdings Inc. revenue, in more detail
Across the 3 fiscal years on record (2018–2020), the highest was $4.80M in fiscal 2019 and the lowest $1.18M in fiscal 2020.
Revenue by fiscal year
ALX Oncology Holdings Inc. revenue, year by year
| Fiscal year | Revenue | Change | Year ended |
|---|---|---|---|
| 2020 | $1.18M | 75.4% down | |
| 2019 | $4.80M | 132.0% up | |
| 2018 | $2.07M | — |
Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.
How it is calculated
Revenue is everything the company billed its customers over the fiscal year — the top line of its income statement.
How to read it
Steady growth in revenue is the raw material for everything else; a fall means the company is selling less or charging less.
ALX Oncology Holdings Inc., figure by figure
- ALX Oncology Holdings Inc. market cap
- ALX Oncology Holdings Inc. earnings
- ALX Oncology Holdings Inc. earnings per share (EPS)
- ALX Oncology Holdings Inc. P/E ratio
- ALX Oncology Holdings Inc. P/S ratio
- ALX Oncology Holdings Inc. P/B ratio
- ALX Oncology Holdings Inc. free cash flow
- ALX Oncology Holdings Inc. operating margin
- ALX Oncology Holdings Inc. dividend
- ALX Oncology Holdings Inc. shares outstanding
- ALX Oncology Holdings Inc. total debt
- ALX Oncology Holdings Inc. cash on hand
- ALX Oncology Holdings Inc. total assets
- ALX Oncology Holdings Inc. return on equity (ROE)
- ALX Oncology Holdings Inc. return on invested capital (ROIC)
ALX Oncology Holdings Inc. (ALXO) overview: price, valuation and scorecard
ALX Oncology Holdings Inc. revenue: questions and answers
What is ALX Oncology Holdings Inc.'s revenue?
ALX Oncology Holdings Inc. (ALXO) reported revenue of $1.18M in fiscal 2020 (the year ended December 31, 2020). That is 75.4% lower than the $4.80M of fiscal 2019.
What are the highest and lowest revenue figures on record for ALX Oncology Holdings Inc.?
Across the 3 fiscal years on record (2018–2020), the highest was $4.80M in fiscal 2019 and the lowest $1.18M in fiscal 2020.
How is ALX Oncology Holdings Inc.'s revenue calculated?
Revenue is everything the company billed its customers over the fiscal year — the top line of its income statement. For ALX Oncology Holdings Inc. it is on record here for 3 fiscal years, 2018 to 2020.
Fiscal years are named for the calendar year they end in.
Learn: revenue
All stocks guides →- Revenue vs earnings vs free cash flow: what each tells you
Revenue is everything a company sold in a period. Earnings, or net income, is what remains after every cost, interest and tax. Free cash flow is the cash operations brought in minus spending on long-lived assets. Revenue shows size and demand, earnings show profitability, and free cash flow shows how much cash the business can actually hand out.
- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- Analyst price targets and ratings: what they mean
An analyst price target is a research analyst's estimate of where a share price will be at a set horizon, such as twelve months; a rating such as buy or hold is that analyst's recommendation. A consensus is an average or median of the targets a data provider has collected. Studies have found targets on average well above later prices.
Cite this page
Funkfolio, “ALX Oncology Holdings Inc. (ALXO) revenue”, data as of 18 November 2026. https://funkfolio.com/stock/ALXO/revenue
Underlying data: the company's filings with the SEC and Yahoo Finance.